Clinical bottom line
Fatigue is a pervasive and debilitating symptom in systemic lupus erythematosus (SLE) that significantly impairs quality of life. Targeted therapies, particularly B cell–directed agents such as belimumab, have demonstrated modest but consistent improvements in patient-reported fatigue outcomes alongside disease activity reduction. However, fatigue in SLE is multifactorial, and pharmacologic interventions alone may be insufficient. Integrating psychoeducational and multidisciplinary approaches remains important. Further research is needed to clarify the mechanisms by which targeted therapies influence fatigue and to optimize management strategies.
What the evidence shows
Belimumab, a monoclonal antibody targeting B lymphocyte stimulator (BLyS), is the most extensively studied targeted therapy with respect to fatigue in SLE. Gomez et al. (2023) synthesized data from clinical trials and real-world cohorts, showing that belimumab treatment is associated with statistically significant improvements in fatigue scores measured by validated instruments such as the FACIT-Fatigue scale. These improvements often parallel reductions in disease activity, suggesting a link between immunologic control and symptom relief.
Other B cell–targeted therapies, including rituximab, have shown variable effects on fatigue, with some studies reporting benefit but limited by small sample sizes and heterogeneous endpoints (Vincent et al., 2021; Moysidou et al., 2023).
Non-biologic targeted agents, such as type I interferon pathway inhibitors, are under investigation but data on fatigue outcomes remain sparse.
Importantly, fatigue in SLE is influenced by psychological factors, sleep disturbances, and comorbidities. Karlson et al. (2004) demonstrated that psychoeducational interventions can improve fatigue and overall well-being, underscoring the need for holistic management.
Reviews by Grech et al. (2013) and Durcan et al. (2016) emphasize that while targeted therapies address immunopathogenesis, adjunctive strategies are necessary to comprehensively manage fatigue.
Caveats and uncertainty
Fatigue measurement is inherently subjective and influenced by multiple confounders, complicating assessment of treatment effects.
Most clinical trials are not powered specifically to evaluate fatigue as a primary endpoint, limiting definitive conclusions.
Heterogeneity in study designs, patient populations, and fatigue assessment tools challenges cross-study comparisons.
The causal relationship between immunologic improvement and fatigue reduction is not fully elucidated; some patients report persistent fatigue despite disease control.
Long-term data on fatigue outcomes with newer targeted agents are lacking.
How this may change practice
Clinicians should consider targeted therapies such as belimumab as part of a comprehensive approach to SLE management that may improve fatigue alongside disease activity.
Routine assessment of fatigue using validated patient-reported outcome measures is recommended to monitor treatment impact.
Multidisciplinary interventions including psychoeducation, physical therapy, and mental health support should be integrated with pharmacologic treatment.
Future research may enable personalized fatigue management by identifying biomarkers predicting response to targeted therapies.
Ongoing education about the multifactorial nature of fatigue can help set realistic expectations and improve patient engagement.